Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP)

British Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2012, Pages 331-334

  Ritter, James M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DOMPERIDONE; ESCITALOPRAM; KETOCONAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; PLACEBO; TERFENADINE;

BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; DISEASE PREDISPOSITION; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG INTERACTION; DRUG SAFETY; EDITORIAL; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; REENTRY ARRHYTHMIA; TORSADE DES POINTES; VOMITING;

ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 84857019812     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04193.x     Document Type: Editorial

References (27)

1. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur Vaiss 1966; 59: 263-72.
2. Allison FG. Syncopal attacks following quinidine administration. Can Med Assoc J 1958; 78: 949-50.
3. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
4. Ritter JM. Editors' view: Drug-induced long QT syndrome and drug development. Br J Clin Pharmacol 2008; 66: 341-4.
5. Molokhia M, Pathak A, Lapeyre-Mestre M, Pharm LC, Montastruc JL, L'Association française des centres régionaux de pharmacovigilance (CRPV), McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol 2008; 66: 386-95.
6. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K, Lorch U, Taubel J. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008; 66: 396-404.
7. Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. Cisapride and ventricular arrhythmia. Br J Clin Pharmacol 2008; 66: 375-85.
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effects of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
9. Waldo AL, Camm AJ, de Ruyder H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
10. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehman MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7.
11. Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E, Soliman EZ, Tomaselli GF, Guallar E. Sex steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2011; 174: 403-11.
12. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90.
13. Somogyi A, Loke KY, Ferro A, Lewis LD, Cohen AF, Ritter JM. Editors' pick 2011. Br J Clin Pharmacol 2012; 73: 4-8.
14. Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 5th Edition. Br J Pharmacol 2011; 164: S1-S324.
15. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008; 154: 1502-7.
16. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer AR. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 2008; 58: 72-6.
17. Salvi V, Karnad DR, Panicker GK, Kothari S. Update on the evaluation of new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010; 159: 34-48.
18. Piccini JP, Whellan DJ, Berridge BR, Finkle J, Pettit SD, Stockbridge N, Valentin JP, Vargas HM, Krucoff MW. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009; 158: 317-26.
19. Akar FG, Yan GX, Antzlevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies re-entrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 2002; 105: 1247-53.
20. Lasser KE, Allen PD, Woolhandle SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-20.
21. Haverkamp W, Breithardt G, Camm AJ etal. The potential for QT prolongation and proarrhythmia by non-ant-arrhythmic drugs: clinical and regulatory implications. Eur Heart J 2000; 21: 1216-31.
22. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
23. Guidance for Industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at (last accessed 4 February 2012).
24. van Gerven J, Cohen A. Vanishing clinical psychopharmacology. Br J Clin Pharmacol 2011; 72: 1-5.
25. van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitolapram in overdose and the effect of activated charcoal. Br J Clin Pharmacol 2012; 73: 402-10.
26. Sugiyama A, Nakamura Y, Nishimura S, Adachi-Akahane S, Kumagai Y, Gayed J, Naseem A, Ferber G, Taubel J, Camm J. Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects. Br J Clin Pharmacol 2012; 73: 455-9.
27. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketokinazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012; 73: 411-21.